Möchten Sie immer auf dem neuesten Stand bleiben?

CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies...

TORONTO and NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American digital infrastructure and energy company, today announced a series of strategic hires...

Acquisition Includes BrewDog’s Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia’s National Retail and...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo...

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new...

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable...

Nasdaq to support the tokenization of equities in a manner that preserves issuer control, existing regulatory frameworks, and the underlying rights associated with company shares  Nasdaq’s equity...

Applied Optoelectronics Inc. (AOI) received its first volume order for 1.6T data center transceivers from one of its long-term major hyperscale customers.

Castle announced new data that confirm that the i31-SLNB accurately predicts SLN positivity and identifies low-risk patients who may safely forgo SLNB.

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for...